This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Today, CoreRx and Aimmune Therapeutics announced their expansion of Myerlake-3. CoreRx is a contract development and manufacturing organization (CDMO) servicing the pharmaceutical and biotechnology industries, and Aimmune is a clinical-stage biopharmaceutical company advancing a therapeutic approach for the treatment of peanut and other food allergies. Jointly, the companies have increased manufacturing operations at CoreRx's ICOT Center campus in Clearwater, Florida.
This new expansion consists of approximately 20,000 square feet of manufacturing and warehouse space at CoreRx's 5733 Myerlake Circle (ML-3) location.
This growth will necessitate additional staffing at CoreRx including positions within pharmaceutical development, manufacturing, engineering, quality assurance and packaging. "The Tampa Bay area is a great place to expand the base of scientific capabilities. These expansions in the Private-sector result in high-paying, skilled roles that contribute immensely to society by providing products and services that impact the quality of lives of Americans. These expansions continue to showcase the Tampa regions expertise in high technology manufacturing on a national and global level." said Todd R. Daviau, President and CEO of CoreRx. "And, we will continue to expand our capabilities to meet the growing demands of our clients."
